Nectar Lifesciences has informed that the board of directors of the company in their meeting held on Monday, March 02, 2026, have, noted, decided and approved the following matters: 1. To acquire 100% paid- up equity share capital of Avensis Exports (‘AEPL’). 2. Change in Registrar and Share Transfer Agent (‘RTA’) of the Company from KFin Technologies (‘KFIN’) to Alankit Assignments (‘AAL’). KFIN will continue to serve as the Company’s RTA until the completion of data transition, shifting of electronic connectivity, and other related procedures, along with receipt of necessary confirmations from NSDL and CDSL. The formalities for change of RTA including documentation, execution of agreement, shifting of electronic connectivity and transition of data will be done by the Company in due course. The details as required under LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and as amended upto date, are provided in: 1. Annexure A for Acquiring 100% paid- up equity share capital of AEPL; and 2. Annexure B for change in RTA from KFIN to AAL. The Board Meeting commenced at 04:00 pm IST and concluded at 04:30 pm IST.

The above information is a part of company’s filings submitted to BSE.